BACKGROUND AND OBJECTIVES: An eight-member group consisting of Canadian infectious disease and immunology specialists and a family physician with significant experience in HIV management was convened to update existing recommendations, specifically intended for use by Canadian HIV-treating physicians, on the appropriate use of enfuvirtide in HIV/AIDS patients with resistance to other antiretroviral drugs. METHODS: Evidence from the literature and expert opinions of the group members formed the basis of the guidelines. Comments on the draft guidelines were obtained from other physicians across Canada with HIV expertise. The final guidelines represent the group's consensus agreement. RESULTS AND CONCLUSIONS: The recommendations were developed to guide physicians in optimal practices in patient selection for enfuvirtide treatment and subsequent patient management. The issues considered include positive predictors of response to enfuvirtide, stage of disease, optimization of the background regimen, early indicators of enfuvirtide response, and patient education and support.
BACKGROUND AND OBJECTIVES: An eight-member group consisting of Canadian infectious disease and immunology specialists and a family physician with significant experience in HIV management was convened to update existing recommendations, specifically intended for use by Canadian HIV-treating physicians, on the appropriate use of enfuvirtide in HIV/AIDSpatients with resistance to other antiretroviral drugs. METHODS: Evidence from the literature and expert opinions of the group members formed the basis of the guidelines. Comments on the draft guidelines were obtained from other physicians across Canada with HIV expertise. The final guidelines represent the group's consensus agreement. RESULTS AND CONCLUSIONS: The recommendations were developed to guide physicians in optimal practices in patient selection for enfuvirtide treatment and subsequent patient management. The issues considered include positive predictors of response to enfuvirtide, stage of disease, optimization of the background regimen, early indicators of enfuvirtide response, and patient education and support.
Authors: Martin Markowitz; Hiroshi Mohri; Saurabh Mehandru; Anita Shet; Leslie Berry; Roopa Kalyanaraman; Alexandria Kim; Chris Chung; Patrick Jean-Pierre; Amir Horowitz; Melissa La Mar; Terri Wrin; Neil Parkin; Michael Poles; Christos Petropoulos; Michael Mullen; Daniel Boden; David D Ho Journal: Lancet Date: 2005 Mar 19-25 Impact factor: 79.321
Authors: Mona R Loutfy; Sharon L Walmsley; Christopher M Mullin; George Perez; James D Neaton Journal: J Infect Dis Date: 2005-09-09 Impact factor: 5.226
Authors: P Richard Harrigan; Brian Wynhoven; Zabrina L Brumme; Chanson J Brumme; Beheroze Sattha; Jennifer C Major; Rafael de la Rosa; Julio S G Montaner Journal: J Infect Dis Date: 2005-03-16 Impact factor: 5.226
Authors: Xiaoping Zhang; Jacob P Lalezari; Andrew D Badley; Albert Dorr; Stanley J Kolis; Tosca Kinchelow; Indravadan H Patel Journal: Clin Pharmacol Ther Date: 2004-06 Impact factor: 6.875
Authors: Bonaventura Clotet; François Raffi; David Cooper; Jean-François Delfraissy; Adriano Lazzarin; Graeme Moyle; Jürgen Rockstroh; Vincent Soriano; Jonathan Schapiro Journal: AIDS Date: 2004-05-21 Impact factor: 4.177
Authors: Joseph A Church; Michael Hughes; Jie Chen; Paul Palumbo; Lynne M Mofenson; Patricia Delora; Elizabeth Smith; Andrew Wiznia; Elizabeth Hawkins; Prakash Sista; Coleen K Cunningham Journal: Pediatr Infect Dis J Date: 2004-08 Impact factor: 2.129